Patients with mitral and tricuspid heart valve disease often have complex conditions with limited treatment options. Our Transcatheter Mitral and Tricuspid Therapies (TMTT) business unit is boldly pursuing an innovative portfolio of technologies to address a
Imagine how your ideas and expertise can change a patient’s life. Patients are at the heart of what we do at Edwards Lifesciences. Our Finance teams work hard to optimize our current and long-term success and
Sr Mgr, Health Economic & Reimbursement This role represents an opportunity to join the Global Health Economics & Reimbursement (GHER) team supporting patient access to innovative transcatheter mitral and tricuspid valve technologies (TMTT) at Edwards Lifesciences.